MEF2A and Alzheimer disease: The MEF2A expression levels were significantly lower in the AD group than in the control group (p < 0.05) in different brain regions (entorhinal cortex, frontal cortex, and temporal cortex), except for the cerebellum, while AsymAD revealed no significant difference (p > 0.05) compared with control.